Trial Profile

A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumurate Switched to Tenofovir Alafenamide Fumarate Based Anti-Retroviral Therapy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir/lamivudine/tenofovir disoproxil fumarate; Medroxyprogesterone
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms BONE:STAR

06 Mar 2024 Results assessing the effect of switching women living with HIV (WLWH) from TDF/ lamivudine/ dolutegravir to Bictergravir /Emtricitabine / TAF (B/F/TAF; Biktarvy) on body composition over a two-year period in the BONE: STAR study presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
06 Apr 2023 Planned End Date changed from 6 Jun 2023 to 31 Mar 2024.
06 Apr 2023 Planned primary completion date changed from 6 Jun 2023 to 31 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com